Joinn Laboratories expands financial product portfolio with new subscriptions

Joinn Laboratories (China) Co. has disclosed a significant financial transaction involving the subscription of wealth management products from the Industrial and Commercial Bank of China (ICBC). The company's subsidiary, Joinn (Suzhou) New Drug, subscribed to two additional ICBC wealth management products on September 19, 2025, bringing the total investment in these products to 410m yuan as of the announcement date. These products are fixed-income, non-principal-guaranteed floating income wealth management products.

The newly subscribed products include the ICBC Wealth Management · Core Selection with a minimum holding period of 7 days (20m yuan, annualized yield 1.6%-2.15%) and the ICBC Wealth Management · Xin Tian Yi with a minimum holding period of 21 days (20m yuan, annualized yield 2.1%-2.4%). This transaction is classified as a disclosable transaction under Chapter 14 of the Listing Rules.

The company believes these investments, which offer higher interest yields than standard bank deposits and flexible redemption options, will optimize the utilization of surplus cash, enhance interest income, and not adversely affect the group's financial position or operations. All terms are considered fair and reasonable, aligning with the overall interests of the company and its shareholders.